NASDAQ:OHRP - Nasdaq -
5.39
+1.25 (+30.19%)
The current stock price of OHRP is 5.39 null. In the past month the price increased by 50.98%. In the past year, price increased by 28.33%.
Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York.
Ohr Pharmaceutical Inc.
800 THIRD AVENUE 11TH FLOOR
NEW YORK NY 10022
CEO: Jason Slakter
Phone: 212-682-8452
The current stock price of OHRP is 5.39 null. The price increased by 30.19% in the last trading session.
The exchange symbol of Ohr Pharmaceutical Inc. is OHRP and it is listed on the Nasdaq exchange.
OHRP stock is listed on the Nasdaq exchange.
Ohr Pharmaceutical Inc. (OHRP) has a market capitalization of 15.25M null. This makes OHRP a Nano Cap stock.
Ohr Pharmaceutical Inc. (OHRP) has a support level at 3.27. Check the full technical report for a detailed analysis of OHRP support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OHRP does not pay a dividend.
Ohr Pharmaceutical Inc. (OHRP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.97).
ChartMill assigns a technical rating of 8 / 10 to OHRP. When comparing the yearly performance of all stocks, OHRP is one of the better performing stocks in the market, outperforming 98.94% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to OHRP. Both the profitability and financial health of OHRP have multiple concerns.
Over the last trailing twelve months OHRP reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS decreased by -259.26% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -92.83% | ||
ROE | -99.27% | ||
Debt/Equity | 0 |